SEATTLE, Sept. 22, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today ...

Publication highlights strong association between a patient's sepsis risk and likelihood of positive cultures, with SeptiCyte RAPID results just 90 minutes after a blood draw SEATTLE and BRISBANE, ...

Study supports utility of host-response testing in febrile neutropenia patients with haematological malignancies which may be the only indication of severe underlying infections SEATTLE and BRISBANE, ...

SEATTLE, Nov. 17, 2020 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced further SeptiCyte® RAPID data ...

SEATTLE, May 9, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the publication in the American Journal of Respiratory and Clinical Care Medicine of the design and results of clinical trials ...

(MENAFN- PR Newswire) BRISBANE, Australia, Aug. 23, 2021 /PRNewswire/ -- Immunexpress , Pty Ltd, a molecular diagnostic company founded in Brisbane, today announced that the SeptiCyte® RAPID test will ...

SEATTLE, Aug. 23, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte ...

SeptiCyte®Lab is a rapid molecular assay that measures a patient’s gene expression level to differentiate between sepsis and infection-negative systemic inflammation. The manuscript describes the ...

Immunexpress Group, Debiopharm Group™ (Debiopharm) and Biocartis have announced a worldwide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage ...

Growing clinical evidence from hospitalized coronavirus patients worldwide indicates that COVID-19 can quickly progress to viral sepsis or bacterial sepsis. The use of SeptiCyte® RAPID can help ...

SEATTLE, Aug. 23, 2022 /PRNewswire/ -- Immunexpress , Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte ...